Current drug delivery最新文献

{"title":"Novel Antibiotic-Loaded PEGylated Xerogels of Acidified Chitosan for Periodontal Diseases.","authors":"Farjad Zafar, Muhammad Ali Sheraz, Syed Abid Ali, Maryam Riaz, Sofia Ahmed, Zubair Anwar","doi":"10.2174/0115672018377472250326061736","DOIUrl":"https://doi.org/10.2174/0115672018377472250326061736","url":null,"abstract":"<p><strong>Objectives: </strong>The primary aim of this study was to develop an effective treatment strategy for periodontal diseases that maximizes therapeutic effects while minimizing systemic adverse effects. Specifically, the study focused on creating a xerogel-based localized drug delivery system for the slow release of doxycycline hyclate (DH) to treat periodontal disease.</p><p><strong>Methods: </strong>Xerogels were prepared using the solvent casting method, with the solvent being evaporated slowly at ambient conditions. The prepared DH xerogels underwent comprehensive characterization to assess their in-silico compatibility, pharmacokinetics, and physicochemical properties. The properties studied included drying time and rate, thickness, moisture content, swelling index, organoleptic properties, scanning electron microscopy, FTIR spectroscopy, differential scanning calorimetry, drug release and kinetics, and antibacterial activity.</p><p><strong>Results: </strong>In-silico studies demonstrated compatibility between the ingredients, indicating minimal adverse effects on the body. The analysis revealed hydrogen bonding between the drug and polymers, changing the drug's crystallization characteristics to an amorphous form. The release profiles of DH from the xerogels indicated a slow release, ranging from 29.42% to 66.30% over 10 hours, following the Hopfenberg model.</p><p><strong>Conclusion: </strong>The findings of this study suggest that the formulated xerogels are well-suited for periodontal applications. The slow-release profile of DH from the xerogels offers a promising approach for localized treatment of periodontal disease, reducing the risk of systemic adverse effects. This data is valuable for dental practitioners and pharmaceutical formulators, providing a new avenue for enhancing periodontal disease treatment.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactoferrin-Conjugated Nanocarriers for Transformative Strategies in Cancer Management: New Insights on Breast Cancer Therapy.","authors":"Rakesh Pahwa, Sanskriti Saini, Gulshan Sharma, Rohil Panwar, Hardeep Singh Tuli, Neeraj Mishra, Sukriti Vishwas, Thakur Gurjeet Singh, Gaurav Gupta, Harish Dureja, Sachin Kumar Singh","doi":"10.2174/0115672018351146250307083901","DOIUrl":"https://doi.org/10.2174/0115672018351146250307083901","url":null,"abstract":"<p><p>Cancer represents a diverse and complex spectrum of diseases characterized by the abnormal growth and proliferation of cells, establishing a formidable global health challenge. Within the array of diverse cancers, breast cancer arises as one of the primary contributors to cancer-related fatalities in females. Breast cysts, thickenings, alterations in breast size or form, etc., are all prevalent and well-known signs of breast cancer. Despite remarkable progression in cancer research and the abundance of potent drugs, the effectiveness of conventional therapy is still hindered by various complications. In this avenue, nanocarriers present considerable promise for delivering therapeutics to cancerous cells, however, still numerous challenges persist in achieving successful targeted drug delivery and localization. Recent progress has emphasized the utilization of ligand-functionalized nanocarriers to enhance the delivery at target tissues and improve uptake by cancer cells. This approach contributes to increased accuracy and efficacy, which ultimately leads to enhanced patient outcomes. Lactoferrin, a multifunctional glycoprotein, is currently receiving significant attention as a promising ligand for targeted drug delivery in cancerous cells, especially breast cancer cells. This review provides new insight into ligand-targeted therapy, emphasizing the key benefits and notable features of utilizing lactoferrin as a targeting ligand for delivering drug-loaded nanocarriers to tumor sites.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143723042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spray-Dried Inhalable Favipiravir Dry Powder Formulation for Influenza Therapy: Preparation and In vivo Evaluation.","authors":"Xinyu Zhang, Baogang Wang, Likun Xu, Liangliang Zhao, Lili Zhang, Zhuchun Bei, Dongna Zhang, Dongsheng Zhou, Meng Lv, Yabin Song","doi":"10.2174/0115672018351326250306040551","DOIUrl":"https://doi.org/10.2174/0115672018351326250306040551","url":null,"abstract":"<p><strong>Background: </strong>Influenza, a seasonal infectious disease, has consistently posed a formidable challenge to global health in recent years. Favipiravir, an RNA-dependent RNA polymerase inhibitor, serves as an anti-influenza medication, currently administered solely in oral form for clinical use. However, achieving an effective therapeutic outcome often necessitates high oral doses, which can be accompanied by adverse effects and suboptimal patient adherence.</p><p><strong>Objective: </strong>To enhance favipiravir delivery efficiency and potentially mitigate dosage-related side effects, this study aimed to formulate favipiravir as a dry powder for pulmonary inhalation, facilitating direct targeting of lung tissue.</p><p><strong>Methods: </strong>Employing L-leucine as a carrier, favipiravir was prepared as an inhalable dry powder through the spray-drying technique. A 3x3 full-factorial design approach was adopted to optimize the formulation. The optimized spray-dried powder underwent comprehensive characterization, including assessments of its morphology, crystallinity, flowability, and aerodynamic particle size distribution. The therapeutic efficacy of the powder was evaluated in a mouse model infected with the H1N1 influenza virus.</p><p><strong>Results: </strong>The formulated powder demonstrated good aerosol properties, rendering it suitable for inhalation delivery. Its therapeutic efficacy was demonstrated in the mouse model, where it exhibited marked protective effects against the virus in vivo after 5 days of treatment. Notably, the inhalation dose required (15 mg/kg/day) was significantly lower than the oral gavage dose (150 mg/kg/day), indicating that substantially reduced doses, when administered via inhalation, were sufficient to confer protection against mortality in mice.</p><p><strong>Conclusion: </strong>The findings underscore the potential of inhalation therapy using spray-dried favipiravir powder as an effective and efficient treatment option for influenza, offering the promise of reduced dosing requirements and associated adverse effects.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA Vaccines: Unlocking Potential, Exploring Applications, and Envisioning Future Horizons.","authors":"Gaurav Mishra, Sunny Rathee, Munish Garg, Umesh K Patil","doi":"10.2174/0115672018320938241121075859","DOIUrl":"https://doi.org/10.2174/0115672018320938241121075859","url":null,"abstract":"<p><p>In recent years, there have been notable strides in developing mRNA vaccines, resulting in the creation of potent immunizations against diverse diseases. This review examines the most recent advancements in this field, focusing on their implications for future vaccine development. The pursuit of heightened vaccine efficacy is investigated through cutting-edge methods in adjuvant selection, delivery system optimization, and antigen selection. The review also explores the potential for personalized vaccines based on genetic profiles, along with the latest techniques to ensure vaccine stability and extend shelf life. Highlighting the versatility of mRNA vaccines in addressing emerging infectious diseases and their variations, the review underscores the significance of swift response plans and advanced technologies to counter evolving viral mutations. In summary, this in-depth analysis emphasizes how mRNA vaccines hold transformative potential in reshaping both therapeutic and preventive strategies. Notable achievements include the creation of extremely potent mRNA vaccinations against the SARS-CoV-2 virus, resulting in the COVID-19 pandemic. Ongoing efforts to address challenges like long-term immune protection and increase the effectiveness and stability of mRNA vaccines are also discussed. This review's main goal is to provide a thorough summary of current advancements in mRNA vaccine technology while exploring how these advances may impact future approaches to treating and preventing different diseases.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Nanotherapeutics and Theranostics for Squamous Cell Carcinoma: A Comprehensive Review.","authors":"Neeraj Sharma, Abhiram Kumar, Sharda Sambhakar, Daksh Bhatia, Sahil Hussain, Mohd Mursal, Bishambar Singh, Kumar Pranav Narayan","doi":"10.2174/0115672018342513241230061704","DOIUrl":"https://doi.org/10.2174/0115672018342513241230061704","url":null,"abstract":"<p><p>Recent advancements in nanotherapeutics have revolutionized cancer treatment through the integration of diagnostic and therapeutic modalities, known as theranostics. This critical review examines the current landscape of nanotherapeutics for various cancers, such as bladder and head and neck squamous cell carcinoma, highlighting current advancements in nanotherapeutics and challenges. Key approaches discussed include biomimetic smart nanocarriers, polymeric smart nanocarriers, inorganic-based smart nanocarriers, and nanorobots. Furthermore, diverse nanomaterials have been explored in theranostics, including liposomes, polymeric nanoparticles, and inorganic nanoparticles such as quantum dots and mesoporous silica nanoparticles. Furthermore, the integration of imaging techniques such as surface-enhanced Raman scattering (SERS) and positron emission tomography (PET) with therapeutic nanoparticles has been analyzed for potential clinical applications.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Studies on the Preparation of a Microemulsion Formulation of Matricaria Recutita Essential Oil and the Treatment of 2,4-Dinitro-Chlorobenzene-Induced Eczema in Mice by Inhibiting Inflammation.","authors":"Dongxu Wang, Wenfei Wang, Qibin Zhang, Chang Liu, Xuefei Li, Kangrui Zuo, Yundong Xie, Xiaofei Zhang","doi":"10.2174/0115672018315617240826133041","DOIUrl":"10.2174/0115672018315617240826133041","url":null,"abstract":"<p><strong>Background: </strong>Eczema, an inflammatory skin disease causing intense itching, is a function of a range of internal and external factors, impacting individuals of all ages and leading to economic loss. Inflammation is the most important manifestation of eczema, and Matricaria recutita essential oil (MREO) extracted from Matricaria recutita possesses excellent antibacterial and anti-inflammatory properties.</p><p><strong>Methods: </strong>In this study, Matricaria recutita microemulsions were prepared by the trans-phase emulsification method and their stability was determined by evaluating the relevant indexes. Establishment of 2,4-dinitro-chlorobenzene-induced AD model in mice. Detection of serum indexes of IL-6, IL-17, and TNF-α, and on pathological tissue sections, the HE staining, toluidine blue staining, immunohistochemistry, and observation were performed.</p><p><strong>Results: </strong>The study obtained optimal conditions for the preparation of microemulsion formulations of Matricaria recutita. Through quality evaluation, it was found that the microemulsion increased stability, reduced irritation, and retained anti-inflammatory activity and therapeutic effects on eczema compared to Matricaria recutita essential oil (MREO). Studies have demonstrated that microemulsion formulations of Matricaria recutita and Matricaria recutita significantly down regulate the proinflammatory factors TNF-α, IL-17, and IL-6. It was shown by hematoxylin-eosin (HE) staining that both Matricaria recutita essential oil (MREO) and Matricaria recutita microemulsion (MRME) improved the inflammatory status of eczematous skin tissues in mice. The number of mast cells expressed in the tissues was decreased in the surface-treated group, as shown by toluidine blue staining. Additionally, the number of mast cells expressed in the tissues in the surface-treated group was reduced, as demonstrated by immunohistochemistry. Furthermore, immunohistochemistry revealed that MREO and MRME have immunomodulatory effects on the tissues.</p><p><strong>Conclusion: </strong>The study showed that microemulsion formulations of Matricaria recutita may serve as a novel remedy for eczema.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"1180-1200"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement in Compatibility and Drug Release Performance of Hot-Melt Pressure-Sensitive Adhesives by Physical Blending Technique.","authors":"Jiayi Yang, Shuo Yin, Tan Wu, Yangyang Zhang, Chunyun Zhu, Nianping Feng, Teng Guo","doi":"10.2174/0115672018339596241120191113","DOIUrl":"10.2174/0115672018339596241120191113","url":null,"abstract":"<p><strong>Background: </strong>Hot-melt Pressure-sensitive Adhesives (HMPSA) are eco-friendly pressuresensitive adhesives, with the potential of being used as substrates for transdermal patches. However, due to the low hydrophilicity of HMPSA, the application is limited in the field of Traditional Chinese Medicine (TCM) plasters.</p><p><strong>Methods: </strong>Three modified HMPSA were prepared with acrylic resin EPO, acrylic resin RL100, and Polyvinylpyrrolidone (PVP) as the modifying materials. The physical compatibility between HMPSA and the modifying materials was investigated through in vitro release performance, viscosity, softening point, cohesion, and fluidity, so as to determine the most effective modifying material. The impact of the modified HMPSA on the release properties of different TCM ingredients was elucidated by the performance of water absorption and contact angle behavior.</p><p><strong>Results: </strong>With the addition of the modifying materials, both the viscosity and the softening point of HMPSA were improved, with the flowability reduced and the cohesion maintained. The morphological and structural changes reflected the physical compatibility between HMPSA and the three modifying materials. According to the results of in vitro release experiments, PVP effectively improved the release performance of paeoniflorin, ephedrine hydrochloride, and cinnamaldehyde in HMPSA, with no significant impact on the release performance of eugenol. The changes in the drug release performance of HMPSA may be attributed to the improved hydrophilicity of HMPSA after physical modification.</p><p><strong>Conclusion: </strong>The compatibility and the drug release performance of HMPSA were effectively enhanced after the addition of the modifying materials by the physical blending technique. Among the three modifying materials, PVP has been found to be an ideal modifying material for HMPSA in the field of TCM plasters due to its effects on drug release performance.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"1459-1468"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alleviation of Tumor Invasion by the Development of Natural Polymer-based Low-risk Chemotherapeutic Systems - review on the Malignant Carcinoma Treatments.","authors":"Vignesh Natarajan","doi":"10.2174/0115672018349688241008220007","DOIUrl":"10.2174/0115672018349688241008220007","url":null,"abstract":"<p><strong>Introduction/objective: </strong>The spread of tumors (48% in men and 51% in women), as well as the protection of malignant tumors by stromal cells and complex blood vessels, pose significant challenges to drug delivery to tumors. Modern chemotherapy, on the other hand, addresses tumor growth suppression by at least 60% through versatile formulation systems and numerous modifications to drug delivery systems. The renewable and naturally occurring polymers present invariably in all living cells form the fundamental foundation for most anticancer drug development. The review aims to discuss in detail the preparations of polysaccharide, lipid, and protein-based drug-loading vehicles for the targeted delivery of prominent anticancer drugs. It also provides an explanation of drug distribution in blood (cumulative releases of nearly 80% drug) and drug accumulation at tumor sites (1-5 mg/kg) due to enhanced permeability and retention (EPR).</p><p><strong>Methods: </strong>Specific delivery examples for treating colorectal and breast carcinomas have been presented to distinguish the varied drug administration, bioavailability, and tumor internalization mechanisms between sugar, fatty acid, and amino acid polymers. Current therapy possibilities based on cutting-edge literature are provided, along with drug delivery systems tailored to tumor location and invasive properties.</p><p><strong>Results: </strong>The unique combinations of the three natural polymers provide unparalleled solutions to minimize the toxicity (<20% drug release) of the chemotherapeutic drugs on normal tissues. Moreover, the development of a consolidated drug delivery system has contributed to a substantial reduction (dose reduction from 10.43 μM to 1.9 μM) in the undesirable consequences of higher dosages of chemotherapeutic drugs.</p><p><strong>Conclusion: </strong>The review extensively covers safe chemotherapeutic systems with significant advantages (tumor volume shrinkage of 4T1 cells from 1000 mm3 to 200 mm³) in clinical applications of carcinoma treatments using natural polymers.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"1240-1264"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12715397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-Stimuli-Responsive Biocompatible Magnetic Nanocarrier as Drug Delivery System to MCF-7 Breast Cancer Cells.","authors":"Sedigheh Ehsanimehr, Kimya Badr, Wim Dehaen, Vahid Shafiei Irannejad, Peyman Najafi Moghadam","doi":"10.2174/0115672018340056240924183806","DOIUrl":"10.2174/0115672018340056240924183806","url":null,"abstract":"<p><strong>Introduction: </strong>The last strategy in targeted drug delivery systems is to deliver the anticancer drug to the tumor tissue to increase its therapeutic effect and minimize its undesirable side effects. In line with this goal in this research, the redox/pH-responsive disulfide magnetic nanocarriers based on PF127-NH₂/L-cysteine-CM-β-CD-FA were synthesized and evaluated in a doxorubicin delivery system.</p><p><strong>Methods: </strong>We effectively surrounded Fe₃O₄ nanoparticles with SiO₂ using the sol-gel method, and then confidently coated them with oleic acid on Fe₃O₄@SiO₂ nanoparticles.. In another reaction, a PF127-NH₂/L-cysteine-CM-β-CD-FA was synthesized. The process involved modifying pluronic F127 (PF 127) with maleic anhydride and aminating it to form PF127-NH₂. The obtained PF127-NH₂ was attached to L-cysteine, followed by condensing with carboxymethyl-β-cyclodextrin and then functionalized by folic acid. Finally, PF127-NH₂/L-cysteine-CM-β-CD-FA was coated on the surface of magnetic nanoparticles, and the resulting PF127-NH₂/L-cysteine-CM-β-CD-FA was disulfidated to form the final nanocarrier network, which was abbreviated as LCMNPs-SS. The doxorubicin was used as a model drug and loaded into the LCMNPs-SS nanocarrier.</p><p><strong>Results: </strong>The LCMNPs-SS nanocarrier exhibited excellent properties for controlled release, with a well-defined release rate, a controllable level by an external magnet, and adjusting by DLdithiothreitol concentration. The LCMNPs-SS nanocarrier could also break apart when exposed to an oxidant or a change in pH. This meant that the drug release could be fine-tuned in response to temperature, pH, or more than one stimulus.</p><p><strong>Conclusion: </strong>These drug-carrying systems are valuable in reducing the dose of doxorubicin. High internalization of the synthesized LCMNPs-SS caused sped cellular uptake.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"1201-1216"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Hydrogel-based Drug Delivery System: A Global Scenario, Current Development, and Future Prospective.","authors":"Momin Firdose Abdul Shukur, Shivani Makhijani, Rahul G Ingle, Maria Saifee","doi":"10.2174/0115672018320746241101052039","DOIUrl":"10.2174/0115672018320746241101052039","url":null,"abstract":"<p><p>Pharmaceutical giants (e.g., Ashland, Bausch & Lomb, Johnson & Johnson, Medtronic, Neurelis, etc.) promote the growth of hydrogels globally. Hydrogel-based drug delivery system (DDS) market size accounted for USD 6415 million in 2021 and is estimated to reach USD 12,357 million by 2030, with a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030. Hydrogels, characterized by their unique three-dimensional networks of hydrophilic polymers, have emerged as a keystone in the advancement of biomaterial science. Existing trends in the advancement of hydrogel drug delivery systems (DDS) involve the release of drugs in response to specific triggers such as pH, temperature, or enzymes for targeted drug delivery and to reduce the potential for systemic toxicity. They excel in their ability to achieve high drug loading capacities, their ease of manufacturing, and their inherent biocompatibility and biodegradability. These attributes not only promise crucial mechanistic features but also offer robust protection for labile drugs and enable the encapsulation of multiple therapeutic agents. Thus, hydrogels stand as promising candidates in various biomedical and pharmaceutical applications, ensuring controlled release and compatibility essential for therapeutic efficacy. Additionally, hydrogels have massive applications in tissue engineering, wound healing, cosmetics, and biomaterials (e.g., contact lenses and implantable devices). Furthermore, hydrogels possess the capability to release active drug(s) under sustained conditions as recommended. Their exceptional qualities position hydrogels as a preferred choice on a global scale. Moreover, they enhance bioavailability, optimize dosage regimens, promote patient compliance, and minimize adverse effects. Furthermore, hydrogels are recommended for use in clinical trials to enhance therapeutic drug delivery outcomes. Despite their remarkable properties, hydrogels do have certain disadvantages, including expensive manufacturing costs and incompatibility with certain drugs. The author has highlighted the fundamental ideas about hydrogels, their classification, global scenario, current developments in the field, and their potential applications. Overall, hydrogel application is progressing rapidly, toward more proficient and effective DDS in the future.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"1376-1392"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}